.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Practice Changing Trials in Advanced Non-Small Cell Lung Cancer

EP. 1: Treatment of Operable Locally Advanced NSCLC

March 1st 2018

EP. 2: Treatment of Unresectable Locally Advanced NSCLC

March 1st 2018

EP. 3: Surgery in the Context of Immunotherapy for Locally Advanced NSCLC

March 1st 2018

EP. 4: Potential for Use of Checkpoint Inhibitors in Early-Stage NSCLC

March 1st 2018

EP. 5: Checkpoint Inhibitors for Newly Diagnosed Stage 4 NSCLC

March 1st 2018

EP. 6: Pembrolizumab + Chemotherapy in Newly Diagnosed NSCLC

March 1st 2018

EP. 7: Immuno-Oncology Combination Therapy: Which Patients With NSCLC?

March 1st 2018

EP. 8: Quadruple Therapy for Newly Diagnosed NSCLC

March 1st 2018

EP. 9: Dual Checkpoint Inhibitor Therapy for NSCLC

March 1st 2018

EP. 10: Biomarkers for Selection of Immuno-Oncology Agents in NSCLC

March 1st 2018

EP. 11: New Standard for Treating Stage 4 EGFR+ NSCLC

March 1st 2018

EP. 12: Treatment of EGFR+ NSCLC Brain Metastases

March 1st 2018

EP. 13: Ongoing Research in EGFR+ NSCLC

March 1st 2018

EP. 14: New Standard of Care for ALK-Rearranged NSCLC

March 1st 2018

EP. 15: Sequencing Therapies for ALK-Rearranged NSCLC

March 1st 2018

EP. 16: Pearls of Wisdom for the Field of NSCLC

March 1st 2018